Imifoplatin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Imifoplatin
- DrugBank Accession Number
- DB17120
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 485.233
Monoisotopic: 485.008067 - Chemical Formula
- C6H16N2O7P2Pt
- Synonyms
- (1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)
- 1,2-cyclohexanediamine pyrophosphatoplatinum(ii), (r,r)-
- Cyclohexane-(1r,2r)-diamineplatinum(ii) diphosphate
- Cyclohexanediamine pyrophosphatoplatinum(ii), (1r,2r)-
- Dihydrogen (sp-4-2)-((1r,2r)-cyclohexane-1,2-diamine-.kappa.2n1,n2)(diphosphato(4)-.kappa.2o1,o3)platinate(2)
- Platinate(2-), ((1r,2r)-1,2-cyclohexanediamine-.kappa.n1,.kappa.n2)(diphosphato(4-)-.kappa.o,.kappa.o'')-, hydrogen (1:2), (sp-4-2)-
- External IDs
- PT 112
- PT-112
- PT112
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- F5I3T42BXC
- CAS number
- 1339960-28-9
- InChI Key
- SCMHTXQHAHWVSX-BNTLRKBRSA-L
- InChI
- InChI=1S/C6H14N2.H4O7P2.Pt/c7-5-3-1-2-4-6(5)8;1-8(2,3)7-9(4,5)6;/h5-6H,1-4,7-8H2;(H2,1,2,3)(H2,4,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
- IUPAC Name
- platinum(2+) (1R,2R)-cyclohexane-1,2-diamine hydrogen (hydrogen phosphonatooxy)phosphonate
- SMILES
- [Pt++].N[C@@H]1CCCC[C@H]1N.OP([O-])(=O)OP(O)([O-])=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 32699547
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Advanced Solid Tumors / CRPC / Genital Neoplasms, Male / Genitourinary tract neoplasm / MCRPC / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Neoplasms by Site / Neoplasms of the Prostate / PT-112 1 2 Recruiting Treatment Recurrent Thymoma / Thymic Epithelial Tumor / Thymus Cancer 1 1 Completed Treatment Multiple Myeloma (MM) 1 1, 2 Completed Treatment Non-Small Cell Lung Cancer (NSCLC) 1 1, 2 Recruiting Treatment Bile Duct Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 38.1 mg/mL ALOGPS logP -0.36 ALOGPS logP -1.4 Chemaxon logS -1 ALOGPS pKa (Strongest Acidic) 1.7 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 129.95 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 23.28 m3·mol-1 Chemaxon Polarizability 9.68 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 16, 2022 21:52 / Updated at July 18, 2023 22:58